share_log

Guggenheim Reiterates Buy on Prime Medicine, Maintains $18 Price Target

Benzinga ·  Dec 4 00:44

Guggenheim analyst Debjit Chattopadhyay reiterates Prime Medicine (NASDAQ:PRME) with a Buy and maintains $18 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment